IntelGenx Technologies (OTCMKTS:IGXT)‘s stock had its “buy” rating reissued by equities research analysts at Echelon Wealth Partners in a research note issued to investors on Tuesday, AnalystRatings.com reports. They presently have a $1.60 price target on the stock. Echelon Wealth Partners’ price objective would suggest a potential upside of 170.04% from the company’s current price.
Several other research analysts have also weighed in on IGXT. ValuEngine upgraded IntelGenx Technologies from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. Maxim Group reiterated a “buy” rating and issued a $1.50 price objective on shares of IntelGenx Technologies in a research report on Friday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $1.00 price objective on shares of IntelGenx Technologies in a research report on Monday. Finally, Zacks Investment Research upgraded IntelGenx Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $1.37.
OTCMKTS IGXT traded down $0.02 during trading hours on Tuesday, reaching $0.59. The company’s stock had a trading volume of 289,175 shares, compared to its average volume of 126,154. IntelGenx Technologies has a 1-year low of $0.39 and a 1-year high of $0.80. The company has a debt-to-equity ratio of 2.76, a current ratio of 2.07 and a quick ratio of 1.92. The firm has a market capitalization of $57.52 million, a price-to-earnings ratio of -4.23 and a beta of 1.84. The company’s 50-day moving average is $0.62 and its two-hundred day moving average is $0.52.
IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease.
Featured Article: Trading Penny Stocks
Receive News & Ratings for IntelGenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.